- Home
- ILLR vs ESPR Comparison
ILLR vs ESPR Comparison
Compare ILLR & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- ESPR
- Stock Information
- Founded
- ILLR 2015
- ESPR 2008
- Country
- ILLR United States
- ESPR United States
- Employees
- ILLR N/A
- ESPR N/A
- Industry
- ILLR Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- ESPR Health Care
- Exchange
- ILLR Nasdaq
- ESPR Nasdaq
- Market Cap
- ILLR N/A
- ESPR 202.2M
- IPO Year
- ILLR N/A
- ESPR 2013
- Fundamental
- Price
- ILLR $0.59
- ESPR $1.20
- Analyst Decision
- ILLR
- ESPR Buy
- Analyst Count
- ILLR 0
- ESPR 6
- Target Price
- ILLR N/A
- ESPR $6.50
- AVG Volume (30 Days)
- ILLR 1.4M
- ESPR 3.1M
- Earning Date
- ILLR 08-15-2025
- ESPR 08-11-2025
- Dividend Yield
- ILLR N/A
- ESPR N/A
- EPS Growth
- ILLR N/A
- ESPR N/A
- EPS
- ILLR N/A
- ESPR N/A
- Revenue
- ILLR $45,244,000.00
- ESPR $259,574,000.00
- Revenue This Year
- ILLR N/A
- ESPR $4.07
- Revenue Next Year
- ILLR N/A
- ESPR N/A
- P/E Ratio
- ILLR N/A
- ESPR N/A
- Revenue Growth
- ILLR N/A
- ESPR 12.99
- 52 Week Low
- ILLR $0.51
- ESPR $0.69
- 52 Week High
- ILLR $6.52
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- ESPR 63.86
- Support Level
- ILLR N/A
- ESPR $1.10
- Resistance Level
- ILLR N/A
- ESPR $1.26
- Average True Range (ATR)
- ILLR 0.00
- ESPR 0.08
- MACD
- ILLR 0.00
- ESPR 0.02
- Stochastic Oscillator
- ILLR 0.00
- ESPR 93.55
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.